Thorium-227 (Th-227) is a potent alpha-emitting radionuclide with a half-life of 18.7 days that decays through a cascade of high-energy alpha particles, making it a powerful candidate for targeted alpha therapy (TAT) against refractory malignancies. Protheragen delivers comprehensive Th-227 radiolabeling solutions—from chelator-vector conjugation and GMP-compliant radiolabeling to preclinical efficacy and biodistribution studies—empowering partners to advance next-generation radiotherapeutics from concept to clinic.
Thorium-227 is an alpha-particle-emitting radionuclide that has gained significant attention in the field of targeted alpha therapy (TAT) due to its favorable nuclear properties and clinical translational potential. With a physical half-life of approximately 18.7 days, Th-227 emits an alpha particle with energy of ~5.0 MeV upon decay to radium-223, initiating a decay chain that ultimately releases five alpha particles and two beta particles before reaching stable lead-207. This multi-emission decay cascade delivers a total energy deposition of approximately 32.4 MeV, conferring exceptionally high linear energy transfer (LET) and potent cytotoxicity capable of inducing irreparable DNA double-strand breaks in target cells. The relatively long half-life of Th-227 is particularly compatible with the pharmacokinetics of monoclonal antibodies and larger targeting vectors, allowing sufficient time for tumor accumulation and sustained therapeutic irradiation.
Fig 1. Drawing of the octadentate hydroxypyridinone thorium-227 complex 1. (Ramdahl, Thomas, et al., 2016)
Unlike radium-223 dichloride—the first approved alpha therapy which is limited to bone metastases due to its intrinsic bone-seeking properties—Th-227 can be stably complexed with suitable chelating agents and conjugated to tumor-targeting biomolecules. This chelation capability enables the development of targeted thorium conjugates (TTCs) that can deliver alpha radiation to a broad spectrum of solid and hematologic malignancies. Current clinical and preclinical investigations have demonstrated promising antitumor efficacy across multiple indications, including prostate cancer, non-Hodgkin lymphoma, ovarian cancer, and mesothelioma, positioning Th-227 as a versatile platform radionuclide in the expanding TAT landscape.
Protheragen provides integrated Th-227 radiolabeling and targeted alpha therapy development services designed to de-risk and accelerate your radiopharmaceutical programs. Leveraging our established partnerships with GMP-compliant radiopharmaceutical manufacturing facilities, specialized preclinical CRO platforms, and clinical trial organizations with deep expertise in nuclear medicine, we offer a seamless pathway from early-stage chelator-vector optimization through IND-enabling studies and clinical supply. Our multidisciplinary team combines radiochemistry expertise, antibody engineering capabilities, and regulatory strategy to deliver robust, reproducible, and regulatory-compliant Th-227 conjugates tailored to your therapeutic target and indication.
We design and synthesize optimized antibody-chelator and peptide-chelator conjugates using state-of-the-art bifunctional chelating agents, including 3,2-HOPO and emerging DOTHOPO ligands, ensuring stable Th-227 complexation and preserved targeting affinity.
We perform comprehensive QC testing including radio-TLC, radio-HPLC, immunoreactive fraction determination, serum stability profiling, and instant thin-layer chromatography to confirm radiochemical purity, specific activity, and construct integrity.
Using established rodent and non-human primate models, we evaluate Th-227 conjugate biodistribution, tumor uptake, normal organ dosimetry, and clearance kinetics to inform first-in-human dose selection and regulatory submissions.
Our partnered preclinical platforms conduct tumor growth inhibition studies in subcutaneous, orthotopic, and metastatic xenograft models, alongside hematology, histopathology, and dosimetry analyses to establish proof-of-concept and safety margins.
Our structured workflow ensures reproducible, high-quality Th-227 radiolabeling from initial vector design to clinical-ready drug product. Each stage is executed under rigorous quality assurance and radiation safety protocols to meet regulatory and scientific standards.
Step 1: Target Assessment & Vector Selection: We evaluate target antigen expression profiles, internalization kinetics, and tissue selectivity to select optimal antibody, peptide, or small-molecule vectors compatible with Th-227 half-life and chelator chemistry.
Step 2: Chelator Conjugate Design & Synthesis: Bifunctional chelators (e.g., 3,2-HOPO, DOTHOPO) are conjugated to targeting vectors via site-specific or lysine-based chemistry, followed by analytical characterization to confirm conjugation efficiency and immunoreactivity.
Step 3: Radiolabeling Process Optimization: Th-227 is complexed to the chelator-vector under optimized pH, temperature, and buffer conditions to achieve high radiochemical yield (>90%), specific activity, and batch-to-batch consistency.
Step 4: Radiochemical Purification & Quality Control: The labeled conjugate is purified to remove unbound radionuclide and subjected to radio-TLC, radio-HPLC, and immunoreactive fraction assays to verify radiochemical purity and construct stability.
Step 5: Formulation, Sterile Filtration & Stability Testing: The final product is formulated in suitable buffer, sterile-filtered, and subjected to real-time and accelerated stability studies under GMP storage conditions to establish shelf-life and release specifications.
Step 6: Preclinical In Vitro & In Vivo Evaluation: Binding affinity, internalization, cytotoxicity, biodistribution, and antitumor efficacy are assessed in relevant cancer models to generate data packages supporting IND submission and clinical translation.
Step 7: Technology Transfer & Clinical Manufacturing Scale-Up: Optimized processes are transferred to GMP manufacturing suites for registration batch and clinical supply production, accompanied by comprehensive documentation and operator training.
Whether you are advancing a first-in-class Th-227 targeted alpha therapy or seeking a reliable partner to scale your radiopharmaceutical program, Protheragen is ready to support your journey from discovery to clinic. Reach out to us today to discuss your Th-227 radiolabeling requirements, explore our service capabilities, or request a customized project proposal tailored to your therapeutic target and development timeline. Our team of radiochemistry and regulatory specialists is available to answer your questions and design a partnership model that aligns with your strategic objectives.
Reference